Cardiol Therapeutics Debt
| CRDL Stock | CAD 2.26 0.05 2.16% |
Cardiol Therapeutics holds a debt-to-equity ratio of 1.0. As of the 29th of November 2024, Short and Long Term Debt Total is likely to drop to about 133.9 K. In addition to that, Net Debt is likely to drop to about (36.4 M) With a high degree of financial leverage come high-interest payments, which usually reduce Cardiol Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Cardiol Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Cardiol Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Cardiol Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Cardiol Therapeutics' stakeholders.
For most companies, including Cardiol Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Cardiol Therapeutics Class, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Cardiol Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 18.0709 | Book Value 0.432 | Return On Assets (0.54) | Return On Equity (1.08) |
Cardiol |
Cardiol Therapeutics Debt to Cash Allocation
Cardiol Therapeutics Class has accumulated 174.34 K in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Cardiol Therapeutics has a current ratio of 24.18, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cardiol Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cardiol Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cardiol Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cardiol to invest in growth at high rates of return. When we think about Cardiol Therapeutics' use of debt, we should always consider it together with cash and equity.Cardiol Therapeutics Total Assets Over Time
Cardiol Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Cardiol Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Cardiol Therapeutics Debt Ratio | 0.47 |
Cardiol Therapeutics Corporate Bonds Issued
Cardiol Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Cardiol Therapeutics Use of Financial Leverage
Leverage ratios show Cardiol Therapeutics' total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Cardiol Therapeutics' financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 174.3 K | 133.9 K | |
| Net Debt | -34.7 M | -36.4 M | |
| Long Term Debt Total | 20.2 K | 19.2 K | |
| Short Term Debt | 15.8 K | 15 K | |
| Net Debt To EBITDA | 1.25 | 1.03 | |
| Debt To Equity | 0.01 | 0.01 | |
| Long Term Debt To Capitalization | 0.01 | 0.01 | |
| Total Debt To Capitalization | 0.01 | 0.01 | |
| Debt Equity Ratio | 0.01 | 0.01 | |
| Cash Flow To Debt Ratio | (0.14) | (0.15) |
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cardiol Stock
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Cardiol Therapeutics Fundamentals Over Time. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.